Zepbound Gets FDA Approval to Treat Sleep Apnea
The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medicationZepbound(tirzepatide) as the first pharmaceutical treatment for moderate-to-severeobstructive sleep apnea (OSA)in adults withobesity. About 17% of people in the United States have moderate or severe OSA, and the condition is more common in older adults and people with obesity. The approval marks a second indication for Zepbound, which was approved to treat overweight and obesity and uses the same active ingredient as the type 2 diabetes medicationMounjaro....